# OnCo record nct03767348 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct03767348/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct03767348", "NCT03767348" ;
  schema:name "Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE)"@en ;
  schema:alternateName "IGNYTE"@en ;
  schema:description "A phase 2 trial of Nivolumab in non-small-cell lung cancer and small-cell lung cancer, run by Replimune, Inc., active and no longer recruiting."@en ;
  schema:url <https://onco.cc/trials/nct03767348/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT03767348> ;
  onco:status "active" ;
  onco:tag "ctgov-ingest" ;
  onco:phase "2" ;
  schema:startDate "2017-09-20" ;
  onco:cancers <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/sclc/>, <https://onco.cc/cancers/melanoma/>, <https://onco.cc/cancers/skin-cancer/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/> ;
  onco:drugs <https://onco.cc/drugs/nivolumab/> ;
  onco:companies <https://onco.cc/companies/replimune/> .